Eli Lilly and Company (TSX:LLY)
42.35
+0.04 (0.09%)
Sep 29, 2026, 3:59 PM EST
Eli Lilly and Company Employees
Eli Lilly and Company had 50,000 employees as of December 31, 2025. The number of employees increased by 3,000 or 6.38% compared to the previous year.
Employees
50,000
Change (1Y)
3,000
Growth (1Y)
6.38%
Revenue / Employee
2.26M CAD
Profits / Employee
758.65K CAD
Market Cap
1.50T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 50,000 | 3,000 | 6.38% |
| Dec 31, 2024 | 47,000 | 4,000 | 9.30% |
| Dec 31, 2023 | 43,000 | 4,000 | 10.26% |
| Dec 31, 2022 | 39,000 | 4,000 | 11.43% |
| Dec 31, 2021 | 35,000 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Eli Lilly and Company News
- 6 hours ago - Eli Lilly reports results from TRIUMPH-2 Phase 3 trial - TheFly
- 6 hours ago - Lilly's experimental drug cuts weight by 21% in diabetes trial - Reuters
- 6 hours ago - Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes - PRNewsWire
- 17 hours ago - Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - Reuters
- 17 hours ago - Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis - TheFly
- 17 hours ago - Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison - PRNewsWire
- 17 hours ago - Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis - Reuters
- 18 hours ago - Eli Lilly announces positive results from study of Foundayo 17.2 mg - TheFly